爱罗咳喘宁对老年COPD急性加重期痰湿阻肺证患者血清中细胞因子及肺功能的影响

Effects of Ailuo Kechuanning on Cytokines Levels in Serum and Pulmonary Function in Elder COPD Patients with Acute Exacerbation and Syndrome of Damp-phelgm Stagnating Lung

目的:观察爱罗咳喘宁口服液对老年慢性阻塞性肺疾病(COPD)急性期痰湿阻肺证患者血清细胞因子及肺功能的影响,评价爱罗咳喘宁对老年COPD急性加重证期痰湿阻肺证患者临床疗效。方法:采用多中心、随机单盲、安慰剂对照的研究方法。选取符合纳入标准的老年COPD急性加重期痰湿阻肺证患者50例,分成对照组(n=25例)和治疗组(n=25例)。两组均在西药治疗的基础上,对照组给予安慰剂治疗,治疗组口服爱罗咳喘宁2.32 g·kg-1·d-1,分2次服连续7 d。观察两组临床症状的改善、肺功能指标及细胞因子白介素-4(interleukin-4,IL-4),IL-8,肿瘤坏死因子-α(tumor necrosis factor alpha,TNF-α)。结果:治疗前两组人口学指标、肺功能及细胞因子IL-8,IL-4,TNF-α无统计学差异。治疗后与对照组总有效率(80%)相比,治疗组总有效率(96%)显著增加(P<0.05);用力肺活量(forced vital capacity,FVC)两组间差异无统计学意义;治疗后治疗组与对照组比较,1秒用力呼气量(forced expiratory volume in 1 second,FEV1)分别为(1.97±0.02,1.61±0.02)m L,FEV1/FVC分别为(60.89±14.87)%,(52.24±16.67)%;细胞因子IL-8分别为(0.42±0.10),(0.48±0.12)μg·L-1,IL-4分别为(0.28±0.09),(0.32±0.06)μg·L-1,TNF-α分别为(0.87±0.40),(1.28±0.25)μg·L-1均较对照组显著降低(均P<0.05)。结论:爱罗咳喘宁口服液可显著降低老年COPD急性加重期痰湿阻肺证患者血清中炎症因子及改善肺功能。

Objective ： To observe the effects of Ailuo Kechuanning （ALKC） on interleukin-4 （IL-4） , interleukin-8 （IL-8）, tumor necrosis factor alpha （TNF-ot） and pulmonary function in elder chronic obstructive pulmonary disease （COPD） patients with acute exacerbation and syndrome of damp-phelgm stagnating the lung. Method： Fifty cases of elder COPD patients with acute exacerbation and syndrome of damp-phelgm stagnating the lung were selected by the muti-center, randomized, single-blind, placebo-controlled clinical trails methods. Fifty cases were randomly divided into two groups, ALKC group （n = 25） and placebo-controlled group （ PC group, n = 25）. On the base of the western drug treatment, ALKC and placebo was used in the control group. Every group was observed in terms of improvement of the symptoms, pulmonary functions, cells factors such as IL-4, IL-8, TNF-α. Result： The differences of demogra-phic, pulmonary functions, cell factors like IL-4, IL-8, TNF-α between two groups had no significant statistical differences prior to our trails. Compared with the PC group, the total effective rate in forced expiratory volume in 1 second （FEV1 ） , FEVl/forced vital capacity （FVC） , IL-8 （0.42±0. 10） μg·L^-1 vs （0.48 ±0. 12） μg·L^-1, （P〈0.05）, TNF-α （0.87±0.40 （P〈0.05）, IL-4 （0.28 ±0.09） μg·L^-1 vs （0.32 ±0.06 ） μg·L^-1 vs （1.28 ±0.25） μg·L^-1, （P〈O. 05） in ALKC group had significant statistical differences （P 〈 0.05, P 〈 0.01 ） , had no significant statistical differences in FVC. Conclusion： ALKC has the improvements action on clinical symptoms, pulmon-ary function and the control of inflammation in elder COPD patients with acute exacerbation and syndrome of damp-phelgm stagnating the lung.